Global Non-Opioid Pain Treatment Market, By Products (Medical Cannabis, Menthol- Containing, Omega 3 Fatty Acid Containing, Botulinum Toxins, Capsaicin Derived), Therapeutic Applications (Orthopaedic and Musculoskeletal Pain, Neuropathic Pain, Cancer Pain, Other Pain), Drug Type (Acetaminophen, Non-steroidal Anti-inflammatory Drugs, Corticosteroids, Anticonvulsants, Serotoninnorepinephrine Reuptake Inhibitor Antidepressants), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Drug Stores, Mail Order Pharmacies) – Industry Trends and Forecast to 2029
Market Analysis and Size
Pain management is an essential part of medical treatment. Migraine, lower back pain, osteoarthritis, fibromyalgia, localised musculoskeletal pain, and localised neuropathic pain are all examples of chronic pain syndromes. While opioids may be acceptable for acute or chronic pain related to palliative or end-of-life care, as well as current cancer therapy, there are also non-opioid pain management choices. Non-opioid pain treatment is an option for mild to moderate pain. Non-opioid pain relief is available without a prescription and as over-the-counter medications.
Data Bridge Market Research analyses that the non-opioid pain treatment market which was USD 622.65 million in 2021, would rocket up to USD 807.32 million by 2029, and is expected to undergo a CAGR of 3.30% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Products (Medical Cannabis, Menthol- Containing, Omega 3 Fatty Acid Containing, Botulinum Toxins, Capsaicin Derived), Therapeutic Applications (Orthopaedic and Musculoskeletal Pain, Neuropathic Pain, Cancer Pain, Other Pain), Drug Type (Acetaminophen, Non-steroidal Anti-inflammatory Drugs, Corticosteroids, Anticonvulsants, Serotoninnorepinephrine Reuptake Inhibitor Antidepressants), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Drug Stores, Mail Order Pharmacies)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Eli Lilly and company (U.S.), Regeneron Pharmaceuticals Inc. (U.S.), Centrexion Therapeutics Corp. (U.S), Acorda Therapeutics (U.S.), Biogen (U.S.), VM Biotech (U.S.), Novartis AG (Switzerland), Alder Biopharmaceuticals (U.S.), Sanofi (France), Pfizer Inc. (U.S.), GSK plc. (U.K.), Hisamitsu Pharmaceutical Co., Inc. (Japan), Clarion (U.S), Endo Pharmaceuticals (Ireland), TEH SENG PHARMACEUTICAL MFG. CO., LTD. (Taiwan), Veridian Healthcare (U.S.), Sorrento Therapeutics, Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Teikoku Seiyaku Co. Ltd. (Japan)
|
|
Market Opportunities
|
|
Market Definition
Non-opioid pain relievers are a form of pain reliever that has been specifically created to manage mild to moderate pain. They're commonly used to treat neuropathic pain, cancer pain, orthopaedic and musculoskeletal pain, and other conditions. Medical cannabis, botulinum toxins, capsaicin derivatives, and other non-opioid pain treatments are among the most common.
Non-Opioid Pain Treatment Market Dynamics
Drivers
- Increasing prevalence of osteoarthritis
The rising global prevalence of osteoarthritis, fueled by the ageing population, joint injuries, obesity, repeated stress on the joint, genetics, metabolic illnesses, and bone abnormalities, is expected to fuel demand for non-opioid pain treatment patches. It is the most prevalent type of arthritis, and it most commonly affects the knees, hips, and hands. According to the Osteoarthritis Action Alliance (OAAA), approximately 54.4 million adults in the United States have some type of arthritis, with that number anticipated to rise to 78 million by 2040. Osteoarthritis affects roughly 32.5 million persons in the United States. This tendency is expected to continue in many regions of the world in the future years, propelling the market forward.
- Increasing cases of cancer
Breast, bowel, colorectal, and lung cancer cases are predicted to increase in the next years, propelling the industry forward. The market is expected to benefit from increased awareness among governments in various countries about the availability of novel non-opioid heat patches for the treatment of cancer-related pain. According to the World Health Organization (WHO), cancer will kill approximately 10 million people worldwide in 2020. Breast cancer claimed over 6,85, 000 lives in the same year, while liver cancer claimed 8,30,000 lives and lung cancer claimed 1.80 million lives. This showcases that the prevalence of cancer is set to surge at a fast pace in the near future, which would drive the market.
- High cases of chronic pain-related conditions
The rising prevalence of chronic pain in India is expected to push the non-opioid pain patch market in South Asia. The market is expected to benefit from the government's increasing investments in the construction of a well-established healthcare infrastructure to treat pain-related disorders. Scientists from the All India Institute of Medical Sciences and the Homi Bhabha National Institute, for example, undertook a study in December 2018 to better understand the effect and magnitude of chronic pain across Southeast Asia. A total of 4326 Indian patients were screened, with 836 of them completing a pain questionnaire. Females had a higher incidence (25.2%) than males, and the prevalence increased dramatically among persons aged 65 and up. The numbers are estimated to grow in the near future, thereby augmenting the demand for non-opioid heat patches in India.
Opportunities
Another important factor expected to boost the market is the growing demand for non-opioid pain management patches due to their ability to reduce the risk of addiction when compared to fentanyl patches when released over a lengthy period of time. In the foreseeable future, the rising demand for minimally invasive therapies is likely to boost growth.
Restraints/Challenges
However, factors such as high cost of patent drugs and use of opioids in various under developed and developing countries will hinder the non-opioid pain treatment market.
This non-opioid pain treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the non-opioid pain treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Non-Opioid Pain Treatment Market
The impact of COVID-19 on the non-opioid pain therapy market is being actively monitored by the QMI team. The clinic's services were severely impacted by the nationwide lockdown and continued rise in infection rates across the country. Many pain and clinic services have seen a decrease in patient visits as a result of COVID-19, resulting in less client engagement. In COVID-19, several clinics and pain services saw a drop in the number of visits.
Recent Development
- In January 2021, a Duke-led team of scientists developed a biocompatible surgical patch that delivers non-opioid medicines to the wound site for days before dissolving. The novel polymer patch administers a regulated release of a medication that blocks the enzyme COX-2 (cyclooxygenase-2,) which is responsible for inflammation and pain.
- In July 2020, the Food and Drug Administration (FDA) in the United States has approved an 8 percent capsaicin patch for the treatment of neuropathic pain in individuals with diabetic peripheral neuropathy of the feet. The patch is a non-opioid, non-systemic, and topical pain therapy that is thought to be the sole way to deliver prescription-strength capsaicin to the patient's skin.
Global Non-Opioid Pain Treatment Market Scope
The non-opioid pain treatment market is segmented on the basis of product, therapeutic application and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Medical Cannabis
- Menthol-Containing
- Omega 3 Fatty Acid-Containing
- Botulinum Toxins
- Capsaicin-Derived
- Others
Therpaeutic application
- Orthopaedic and Musculoskeletal Pain
- Neuropathic Pain
- Cancer Pain
- Post-operative Pain
- Others
Distribution channel
- Hospitals Pharmacies
- Retail Pharmacies
- Drug Stores
- Mail Order Pharmacies
Non-Opioid Pain Treatment Market Regional Analysis/Insights
The non-opioid pain treatment market is analysed and market size insights and trends are provided by country, product, therapeutic application and distribution channel as referenced above.
The countries covered in the non-opioid pain treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the non- opioid pain treatment market due to growing clinical trials and increasing funding by the government.
Asia-Pacific is expected to show significant growth, due to changing economic demographic which improves the drug affordability, rising health insurance and low cost of production and R&D boosts efficiency of pharmaceutical companies in the emerging countries such as India.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Non-Opioid Pain Treatment Market Share Analysis
The non-opioid pain treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to non-opioid pain treatment market.
Some of the major players operating in the non-opioid pain treatment market are:
- Eli Lilly and company (U.S.)
- Regeneron Pharmaceuticals Inc. (U.S.)
- Centrexion Therapeutics Corp. (U.S.)
- Acorda Therapeutics (U.S.)
- Biogen (U.S.)
- VM Biotech (U.S.)
- Novartis AG (Switzerland)
- Alder Biopharmaceuticals (U.S.)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc. (U.K.)
- Hisamitsu Pharmaceutical Co., Inc. (Japan)
- Clarion (U.S.)
- Endo Pharmaceuticals (Ireland)
- TEH SENG PHARMACEUTICAL MFG. CO., LTD. (Taiwan)
- Veridian Healthcare (U.S.)
- Sorrento Therapeutics, Inc. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Teikoku Seiyaku Co. Ltd. (Japan)
SKU-